KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Common Equity: 2016-2024

Historic Common Equity for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to $10.9 billion.

  • Moderna's Common Equity fell 21.77% to $9.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 billion, marking a year-over-year decrease of 21.77%. This contributed to the annual value of $10.9 billion for FY2024, which is 21.32% down from last year.
  • Moderna's Common Equity amounted to $10.9 billion in FY2024, which was down 21.32% from $13.9 billion recorded in FY2023.
  • In the past 5 years, Moderna's Common Equity ranged from a high of $19.1 billion in FY2022 and a low of $2.6 billion during FY2020.
  • Its 3-year average for Common Equity is $14.6 billion, with a median of $13.9 billion in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 452.32% in 2021, then declined by 27.55% in 2023.
  • Moderna's Common Equity (Yearly) stood at $2.6 billion in 2020, then spiked by 452.32% to $14.1 billion in 2021, then spiked by 35.19% to $19.1 billion in 2022, then dropped by 27.55% to $13.9 billion in 2023, then dropped by 21.32% to $10.9 billion in 2024.